Unapproved research chemicalNo human evidence

Epitalon

Also referred to as Epithalon, Epithalamin, AEDG

Widely marketed for longevity. The evidence originates almost entirely from a single research programme and has not been independently replicated.

Molecule class: Synthetic tetrapeptide (Ala-Glu-Asp-Gly)
Category: Longevity
Last evidence review: 2026-08-24

Compare this compound Check interactions Solution calculator

Human studies

Animal / in vitro

Graded claims

—

Participants

Mechanism

What is being studied

Proposed effects on telomerase activity and pineal melatonin rhythm. These proposals derive from the originating programme and are not established.

Evidence

Claims, graded individually

Each statement below carries its own evidence level, its own confidence rating, and its own account of what remains unestablished. A compound does not have a single grade.

Aging & Longevity Research

XInsufficient / conflictingVery low confidenceNo human evidence

Epitalon has been reported by its originating research programme to influence telomerase activity and melatonin rhythm.

What is not established

Evidence originates almost entirely from one programme, much of it outside mainstream indexing, without independent replication.

Supporting sources (1)

Observational studyHumanNo verified identifier on file

Epitalon (epithalon) and telomerase/pineal literature

Khavinson VK and colleagues · Predominantly Russian-language gerontology literature · 2003

Population: Small elderly cohorts in the originating research programme
Endpoint: Telomerase activity, melatonin rhythm, mortality in cohort follow-up
Route: Intramuscular and intranasal in the reported work
Quantity as reported: Reported in the originating literature only
Frequency: Varies

Result. The originating programme reported favourable findings.

Adverse events. Not systematically characterised.

Limitations. Evidence originates almost entirely from a single research programme, much of it not indexed in mainstream databases and not independently replicated. Treat directional claims with substantial caution.

Search PubMed for this literature →

Last evidence review: 2026-08-23

Human evidence

1 human study catalogued

Human and non-human evidence are kept strictly separate. They are never pooled, averaged, or presented as a single body of support.

Observational studyHumanNo verified identifier on file

Epitalon (epithalon) and telomerase/pineal literature

Khavinson VK and colleagues · Predominantly Russian-language gerontology literature · 2003

Population: Small elderly cohorts in the originating research programme
Endpoint: Telomerase activity, melatonin rhythm, mortality in cohort follow-up
Route: Intramuscular and intranasal in the reported work
Quantity as reported: Reported in the originating literature only
Frequency: Varies

Result. The originating programme reported favourable findings.

Adverse events. Not systematically characterised.

Search PubMed for this literature →

Pharmacology

Reported parameters

Half-life

Not characterised

Not characterised in accessible published pharmacokinetic work.

Routes studied

Intramuscular
Intranasal

Evidence from one route does not transfer to another. Topical, oral, and injected administration can produce entirely different exposure from the same quantity.

Regulatory status

Not approved for human use in the United States. FDA removed epitalon from the Category 2 list effective 22 April 2026, and the Pharmacy Compounding Advisory Committee voted favourably on 23-24 July 2026. Neither is an approval.

Storage as documented

No approved labelling exists.

Safety

Signals reported in the literature

This lists what has been reported. It is not a complete safety profile, and for several compounds in this catalogue no systematic safety surveillance exists at all.

Human safety is not systematically characterised
Any compound proposed to influence telomerase raises an unresolved theoretical question about cell proliferation

Limitations

What the evidence cannot tell you

Given as much prominence as the findings, because for most compounds in this category it is the more important half.

Evidence concentrated in one research programme, much of it outside mainstream indexing
No independent replication of the principal claims
The gap between marketing confidence and evidence strength is unusually wide for this compound

Reference

Evidence grading key

AStrong

Multiple high-quality human trials, or strong systematic-review or meta-analytic evidence.

BModerate

Human controlled evidence exists, but replication or sample size is limited.

CPreliminary

Small human studies, observational evidence, or early-phase clinical work.

DPreclinical

Predominantly animal or in-vitro evidence. No adequate human outcome data.

EMechanistic

Biological plausibility or mechanistic reasoning without adequate outcome evidence.

XInsufficient / conflicting

Evidence is absent, irreconcilable, or too weak to support any directional statement.

Other compounds studied in the same research areas

NAD+ and precursors

Included because it appears constantly alongside peptides. Oral precursors reliably raise blood NAD+. Downstream functional benefits have been inconsistent.